Chronic Spontaneous Urticaria is a skin disease characterized by the presence of hives or wheals lasting for six weeks or more without a clear trigger or cause. This condition involves the activation of mast cells in the skin, leading to the release of histamines, leukotrienes, and chemokines. As a result, patients experience persistent itching, swelling, and skin inflammation, which can continue for years or even decades.
The company we are profiling today is Celldex Therapeutics Inc. (CLDX), which is conducting one of the largest global phase III programs in Chronic Spontaneous Urticaria with its investigational drug Barzolvolimab.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com